Purpura thrombotique thrombocytopénique médié par des anticorps anti-ADAMTS13 après un traitement par interféron-alpha 2 a pégylé et ribavirine chez une patiente atteinte d’hépatite C chronique

Lambot, Frédéric); Hanson, Bernard; Sztern, B

doi:10.1016/j.lpm.2010.04.016

Cited by 6 publications

(2 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Apart from 2 deaths, the other seven patients responded to plasmapheresis very early. 12-14 Lambert et al 14 reported a case of interferon related TTP in a patient with chronic hepatitis C. Unlike our patient, she responded to plasmapheresis very early and was not treated with Rituximab. In all the 9 cases, none of them were treated with Rituximab.…”

Section: Discussioncontrasting

confidence: 48%

“…TTP in chronic hepatitis C patients on interferon treatment has been treated with plasmapheresis and steroid in six of the 9 earlier reported cases with relative success. 9-11,14 Two of the nine patients had a fatal outcome. Successful treated of an initial episode of acute refractory TTP with Rituximab and plasmapheresis in a patient on interferon therapy for chronic hepatitis C has not been reported.…”

Section: Introductionmentioning

confidence: 98%

See 1 more Smart Citation

Thrombotic Thrombocytopenic Purpura in a Patient with Interferon Treated Hepatitis C Successfully Treated with Rituximab

Poddar

Wang

2013

Hematology Reports

View full text Add to dashboard Cite

Thrombotic thrombocytopenic purpura (TTP) is a life threatening condition associated with formation of platelet thrombi. Deficiency of ADAM TS 13 with presence of inhibitory anti-ADAM TS 13 Immunoglobulin G antibody is seen in patients with acquired TTP. TTP in patients on interferon therapy for chronic hepatitis C has rarely been reported. Furthermore, successful treatment of an initial episode of acute refractory acquired TTP, in a patient of chronic hepatitis C during interferon therapy with Rituximab, has not been previously reported. Here we describe a case of acute refractory acquired TTP associated with pegylated interferon therapy for her chronic hepatitis C infection. Initially refractory to plasmapheresis and steroids, she was successfully treated with Rituximab and plasmaphersis without any evidence of reactivation of hepatitis.

show abstract

Section: Discussioncontrasting

confidence: 48%

Section: Introductionmentioning

confidence: 98%

Thrombotic Thrombocytopenic Purpura in a Patient with Interferon Treated Hepatitis C Successfully Treated with Rituximab

Poddar

Wang

2013

Hematology Reports

View full text Add to dashboard Cite

show abstract

Interferon induced thrombotic microangiopathy (TMA): Analysis and concise review

Kundra

Wang

2017

Critical Reviews in Oncology/Hematology

View full text Add to dashboard Cite

Drug‐induced thrombotic thrombocytopenic purpura: A systematic review and review of European and North American pharmacovigilance data

et al. 2022

View full text Add to dashboard Cite

Summary Many medications have been reported to be associated with thrombotic thrombocytopenic purpura (TTP) through pharmacovigilance data and published case reports. Whilst there are existing data available regarding drug‐induced thrombotic microangiopathy, there is no available synthesis of evidence to assess drug‐induced TTP (DI‐TTP). Despite this lack of evidence, patients with TTP are often advised against using many medications due to the theoretical risk of DI‐TTP. This systematic review evaluated the evidence for an association of medications reported as potential triggers for TTP. Of 5098 records available 261 articles were assessed further for eligibility. Fifty‐seven reports, totalling 90 patients, were included in the final analysis. There were no cases where the level of association was rated as definite or probable, demonstrating a lack of evidence of any drug causing DI‐TTP. This paucity of evidence was also demonstrated in the pharmacovigilance data, where 613 drugs were reported as potential causes of TTP without assessment of the strength of association. This systematic review demonstrates the need for standardised reporting of potential drugs causing TTP. Many reports omit basic information and, therefore, hinder the chance of finding a causative link if one exists.

show abstract

Purpura thrombotique thrombocytopénique médié par des anticorps anti-ADAMTS13 après un traitement par interféron-alpha 2 a pégylé et ribavirine chez une patiente atteinte d’hépatite C chronique

Cited by 6 publications

References 14 publications

Thrombotic Thrombocytopenic Purpura in a Patient with Interferon Treated Hepatitis C Successfully Treated with Rituximab

Thrombotic Thrombocytopenic Purpura in a Patient with Interferon Treated Hepatitis C Successfully Treated with Rituximab

Interferon induced thrombotic microangiopathy (TMA): Analysis and concise review

Drug‐induced thrombotic thrombocytopenic purpura: A systematic review and review of European and North American pharmacovigilance data

Contact Info

Product

Resources

About